Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Investigation of the pentamidine efficacy against myotonic dystrophy type 1 exploiting polymeric- and lipid-based nanoparticles. Local targets link to admitted publications; unresolved targets remain external evidence.
The myotonic dystrophy expanded CUG repeat tract is necessary but not sufficient to disrupt C2C12 myoblast differentiation
10.1093/hmg/10.18.1879 · 2001 · External reference
L-Carnitine functionalization to increase skeletal muscle tropism of PLGA nanoparticles
10.3390/ijms24010294 · 2022 · External reference
Nanomedicine for gene delivery and drug repurposing in the treatment of muscular dystrophies
10.3390/pharmaceutics13020278 · 2021 · External reference
Polymeric nanoparticles for drug delivery
10.1021/acs.chemrev.3c00705 · 2024 · External reference
Advancements in the use of nanopharmaceuticals for cancer treatment
10.1177/10781552241251757 · 2024 · External reference
An ex vivo experimental system to track fluorescent nanoparticles inside skeletal muscle
2023 · External reference
Rationally designed hyaluronic acid-based nano-complexes for pentamidine delivery
2019 · External reference
Alcian blue staining to track the intracellular fate of hyaluronic-acid-based nanoparticles at transmission electron microscopy
10.4081/ejh.2019.3086 · 2019 · External reference
Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules
10.1038/ncomms3044 · 2013 · External reference
Fluorescence and electron microscopy to visualize the intracellular fate of nanoparticles for drug delivery
10.4081/ejh.2016.2640 · 2016 · External reference
Embedding cell monolayers to investigate nanoparticle-plasmalemma interactions at transmission electron microscopy
10.4081/ejh.2019.3026 · 2019 · External reference
Cell uptake and intracellular fate of phospholipidic manganese-based nanoparticles
10.1016/j.ijpharm.2016.05.019 · 2016 · External reference
Uptake and intracellular fate of biocompatible nanocarriers in cycling and noncycling cells
10.2217/nnm-2018-0148 · 2019 · External reference
Therapeutic effects of dexamethasone-loaded hyaluronan nanogels in the experimental cholestasis
10.1007/s13346-022-01132-7 · 2022 · External reference
Mir-206 partially rescues myogenesis deficiency by inhibiting CUGBP1 accumulation in the cell models of myotonic dystrophy
10.1080/01616412.2018.1493963 · 2019 · External reference
Therapeutics development in myotonic dystrophy type 1
10.1002/mus.22090 · 2011 · External reference
Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy
10.1089/hum.2012.212 · 2013 · External reference
Nuclear ribonucleoprotein-containing foci increase in size in non-dividing cells from patients with myotonic dystrophy type 2
10.1007/s00418-012-0984-6 · 2012 · External reference
Uptake and intracellular distribution of different types of nanoparticles in primary human myoblasts and myotubes
10.1016/j.ijpharm.2019.02.017 · 2019 · External reference
Unresolved reference
External reference
The effect of PEGylated iron oxide nanoparticles on sheep ovarian tissue: an ex-vivo nanosafety study
10.1016/j.heliyon.2020.e04862 · 2020 · External reference
High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell lines
10.1093/hmg/ddt542 · 2014 · External reference
Unresolved reference
2011 · External reference
RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1
10.1073/pnas.1117019109 · 2012 · External reference
Pathogenic mechanisms of myotonic dystrophy
10.1042/bst0371281 · 2009 · External reference
Modeling myotonic dystrophy 1 in C2C12 myoblast cells
2016 · External reference
Global prevalence of myotonic dystrophy: an updated systematic review and meta-analysis
10.1159/000524734 · 2022 · External reference
A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives
10.3390/molecules27041372 · 2022 · External reference
Internalized chitosan nanoparticles persist for long time in cultured cells
10.4081/ejh.2015.2492 · 2015 · External reference
Myotonic dystrophies: an update on clinical aspects, genetic, pathology, and molecular pathomechanisms
2015 · External reference
Chasing bacteria within the cells using levofloxacin-loaded hyaluronic acid nanohydrogels
10.1016/j.ejpb.2014.03.003 · 2014 · External reference
One-step formation and sterilization of gellan and hyaluronan nanohydrogels using autoclave
10.1007/s10856-014-5362-6 · 2015 · External reference
Intracellular delivery of natural antioxidants via hyaluronan nanohydrogels
10.3390/pharmaceutics11100532 · 2019 · External reference
Biodistribution and intracellular localization of hyaluronan and its nanogels. A strategy to target intracellular S. aureus in persistent skin infections
10.1016/j.jconrel.2020.06.007 · 2020 · External reference
Hyaluronan-based nanohydrogels for targeting intracellular S. aureus in human keratinocytes
2018 · External reference
Halting hyaluronidase activity with hyaluronan-based nanohydrogels: development of versatile injectable formulations
10.1016/j.carbpol.2019.06.004 · 2019 · External reference
CD44 regulates myoblast migration and differentiation
10.1002/jcp.20724 · 2006 · External reference
In vitro interaction of colloidal nanoparticles with mammalian cells: what have we learned thus far?
10.3762/bjnano.5.161 · 2014 · External reference
Hyaluronic acid cloaked oleic acid nanoparticles inhibit MAPK signaling with sub-cellular DNA damage in colon cancer cells
10.1039/c7tb00656j · 2017 · External reference
Redox/pH dual stimuli-responsive biodegradable nanohydrogels with varying responses to dithiothreitol and glutathione for controlled drug release
10.1016/j.biomaterials.2012.05.062 · 2012 · External reference
Strategies to obtain encapsulation and controlled release of pentamidine in mesoporous silica nanoparticles
10.3390/pharmaceutics10040195 · 2018 · External reference
Hyaluronic acid nanohydrogel loaded with quercetin alone or in combination to a macrolide derivative of rapamycin RAD001 (Everolimus) as a new treatment for hormone-responsive human breast cancer
10.1002/jcp.25587 · 2017 · External reference
Nanohydrogels: advanced polymeric nanomaterials in the era of nanotechnology for robust functionalization and cumulative applications
10.3390/ijms23041943 · 2022 · External reference
Repurposing the anti-parasitic agent pentamidine for cancer therapy; a novel approach with promising anti-tumor properties
10.1186/s12967-025-06293-w · 2025 · External reference
Repurposing pentamidine using hyaluronic acid-based nanocarriers for skeletal muscle treatment in myotonic dystrophy
2023 · External reference
Myotonic dystrophies: an update on clinical features, molecular mechanisms, management, and gene therapy
10.1007/s10072-024-07826-9 · 2025 · External reference
Pentamidine-loaded lipid and polymer nanocarriers as tunable anticancer drug delivery systems
10.1016/j.xphs.2019.11.011 · 2020 · External reference
Tetrazolium salts and formazan products in cell biology: viability assessment, fluorescence imaging, and labeling perspectives
10.1016/j.acthis.2018.02.005 · 2018 · External reference
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
10.1016/j.addr.2015.09.012 · 2016 · External reference
Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial
10.1016/s1474-4422(23)00001-7 · 2023 · External reference
Effect of surface properties on nanoparticle-cell interactions
10.1002/smll.200901158 · 2010 · External reference
Unresolved reference
External reference
Pentamidine reverses the splicing defects associated with myotonic dystrophy
10.1073/pnas.0903234106 · 2009 · External reference
Targeting nuclear RNA for in vivo correction of myotonic dystrophy
10.1038/nature11362 · 2012 · External reference
Systematic investigation on the intracellular trafficking network of polymeric nanoparticles
10.1039/c7nr00532f · 2017 · External reference
Hyaluronan-cholesterol nanogels for the enhancement of the ocular delivery of therapeutics
10.3390/pharmaceutics13111781 · 2021 · External reference
